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neural connections trace to sympathetic centers of the central nervous system in normal mice. However,
this was markedly reduced in type 1 diabetes, suggesting a signiﬁcant loss of bone marrow innervation.
This loss of innervation was associated with a change in hematopoiesis toward generation of more
monocytes and an altered diurnal release of monocytes in rodents and patients with type 1 diabetes. In
the hypothalamus and granular insular cortex of mice with type 1 diabetes, bone marrowederived
microglia/macrophages were activated and found at a greater density than in controls. Inﬁltration of
CD45þ/CCR2þ/GR-1þ/Iba-1þ bone marrowederived monocytes into the hypothalamus could be mitigated
by treatment with minocycline, an anti-inﬂammatory agent capable of crossing the blood-brain barrier.
Our studies suggest that targeting central inﬂammation may facilitate management of microvascular
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T.C.-L. and M.B.G. contributed equally to this work as senior authors.Diabetes is responsible for 60% of all deaths worldwide and is
one of the world’s major causes of premature illness and death
(WorldHealthOrganization, http://www.who.int/mediacentre/
factsheets/fs312/en, last accessed September 10, 2013). Vas-
cular complications, including cardiovascular disease, diabetic
retinopathy and neuropathy, and kidney failure, are largely
responsible for the marked risk of premature death seen in
individuals afﬂicted with diabetes. Chronic hyperglycemia
leads to pathological characteristics of both the peripheral and
central nervous systems (CNS).1 Oxidative stress, abnormal
lipid metabolism, impaired vascular reactivity with reduced
bloodﬂow, and neuroinﬂammationhavebeen implicated in the
pathogenesis of both peripheral neuropathy and CNS disease
associated with diabetes.2 Although the origins of this neuro-
inﬂammation are incompletely understood, both local and
systemic inﬂammatory cells are believed to contribute to these
pathological characteristics.
A functional link between the sympathetic nervous
system (SNS) and bone marrow cells has long beenstigative Pathology.
.appreciated,3 and the regulation of inﬂammatory cell
release from the bone marrow is part of normal immuno-
surveillance.4 By modulating the immune system, the SNS
inﬂuences the pathophysiological characteristics of a wide
spectrum of diseases, including cardiovascular diseases.5
Direct sympathetic innervation of the immune organs,
including bone marrow, spleen, and lymph nodes,6 and
increased splenic sympathetic nerve activity, induced by
angiotensin II infusion in the CNS, have been shown to
enhance the splenic immune response.7 In conditions such
as neurogenic hypertension, the paraventricular nucleus
CNS Inﬂammation in T1D(PVN) of the hypothalamus (HYPO) exhibits sympathetic
hyperactivity that is associated with neuroinﬂammation.5,8
In contrast, stimulation of the vagus nerve exerts anti-
inﬂammatory effects by decreasing levels of the inﬂam-
matory cytokines and suppressing the activation of
immune cells.9
Although, in health, the release of bone marrow cells into
the circulation is dynamically and precisely regulated, in
disease, this release can be altered.10 We have previously
shown that, in diabetes, the circadian pattern of hematopoietic
stem cell (HSC) release is dampened and phase shifted.11 The
regulation of leukocyte generation and hematopoiesis as
a whole is achieved by intimate intracellular interactions
between developing blood cells and stromal elements, which
release cytokines in response to neural stimulation.12 This
direct cellular association between bone marrow stromal cells,
HSCs, and nerve terminals is described as the neuroreticular
complex.12 Within the healthy bone marrow compartment,
there exists an optimal balance between lymphoid andmyeloid
differentiation of HSCs, producing 10% myeloid and 90%
lymphoid cells. However, with aging, for example, this
balance shifts toward more myeloid and fewer lymphoid cell
types.13e15 Changes in hematopoiesis and immune function
associated with aging have, in the past, been correlated with
regression of neural innervations from the marrow.16
Circulating monocytes are divided into two subsets: one
expresses Ly6C/Gr-1 at high levels (Ly6Chi), representing
50% to 60% of the monocyte pool in steady state and which is
a potent inﬂammatorymediator (proinﬂammatory subset), and
the other expresses Ly6C at low levels. Ly6Clo monocytes are
termed resident or homeostatic because they trafﬁc through
noninﬂamed tissues, perform surveillance functions, and
resolve inﬂammation.17 Cysteine chemokine ligand 2 (CCL2)
is a chemoattractant that increasesmonocyte release frombone
marrow, facilitates monocyte accumulation at the vessel wall
and transmigration across microvascular endothelial cell
layers, and attracts cysteine chemokine receptor 2þ (CCR2þ)
monocytes into inﬂamed tissue.18e22 Increased expression
of CCL2 mRNA has been seen in the retina and kidney of
diabetic mice.23 Based on the expression of the receptor for
CCL2 (CCR2), mouse Ly6Chi are CCR2þ monocytes,
whereas Ly6Clo are characterized as CCR2.
In this study, we examined the impact of type 1 diabetes
(T1D) on bonemarrow andCNS.We studied the following: i)
the connections between bone marrow and the CNS using
pseudorabies virus (PRV)etracing studies; ii) the con-
tribution of bone marrowederived cells in CNS neuro-
inﬂammation using a time course study of gfp chimeric mice
made diabetic with streptozotocin (STZ); iii) the phenotype of
the cells in speciﬁc CNS regions using ﬂow cytometry and the
expression of cytokines in these same regions; iv) changes in
peripheral nerves innervating the bone marrow, cytokine
expression within the bone marrow, and cellular composition
of the bone marrow; and v) the effect of minocycline, an anti-
inﬂammatory agent capable of crossing the blood-brain
barrier (BBB), on neuroinﬂammation in T1D mice.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Human Studies
The study was approved by University of Florida (Gaines-
ville) Institutional Review Board 407-2010. All study
subjects signed an informed consent. To accomplish our
studies, patients were brought into the Center for Trans-
lational Science Institute for 48 hours. During the ﬁrst 24
hours, patients were evaluated, and on the evening of the ﬁrst
day, a heparin lock was placed. During the second 24 hours,
the patients had 1 mL of blood removed every 2 hours and
this blood was used for ﬂuorescence-activated cell sorter
analysis to enumerate the monocytes. Both diabetic (nZ 3)
and nondiabetic (nZ 3) patients were examined.
Patient Characteristics
Patients were chosen based on the diagnosis of type 1 dia-
betes based on clinical history and fasting C-peptide level of
<0.1 nmol/L. The daily insulin dose for these individuals was
a total 45  13 U per day, with basal insulin units of 22  7
and hemoglobin A1C of 7.0  0.4. Controls were deemed
healthy and matched for age and sex to the diabetic subjects.
Inclusion Criteria
Those aged between 21 and 65 years were eligible to
participate.
Exclusion Criteria
The exclusion criteria were as follows: i) evidence of
ongoing acute or chronic infection (HIV, hepatitis B or C, or
tuberculosis); ii) ongoing malignancy; iii) cerebral vascular
accident or cerebral vascular procedure; iv) current preg-
nancy; v) history of organ transplantation; vi) presence of
a graft; vii) uremic symptoms, an estimated glomerular
ﬁltration rate of <20 mL/minute (by a Modiﬁcation of Diet
in Renal Disease equation), or an albumin level of <3.6 (to
avoid malnutrition as a confounding variable); viii) smoking
history; and ix) anemia.
Animals
Male Wistar rats were obtained from Charles River (Wil-
mington, MA). C57Bl6 mice and transgenic mice homo-
zygous for green ﬂuorescent protein (GFPþ) were obtained
from the Jackson Laboratory (Bar Harbor, ME), and
housed in the institutional animal care facilities at the
University of Florida. All animals were treated in accor-
dance with the Guiding Principles in the Care and Use of
Animals (NIH, Bethesda, MD) and the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research. All
experiments were approved by the Institutional Animal
Care and Use Committee of the University of Florida.1609
Hu et alExperimental Diabetes
Experimental diabeteswas induced as previously described.24,25
C57Bl/6J mice (Jackson Laboratory), aged 7 to 10 weeks,
were rendered diabetic with ﬁve consecutive daily 55 mg/kg
i.p. injections of STZ freshly dissolved in citrate buffer (pH
4.5). For rats, a single injection of 60 mg/kg was used.
Development of diabetes (deﬁned by a blood glucose level of
>250 mg/dL) was veriﬁed 1 week after the ﬁrst STZ injection
(Glucometer Elite XL; Bayer Corp, Elkhart, IN). Glycemic
control was estimated on multiple occasions from the mea-
surement of glycohemoglobin, using either a glacated hemo-
globin assay (Glyc-Afﬁn; PerkinElmer, Norton, OH) or a
glycohemoglobin assay (Helena Glyco Tek Laboratory,
Beaumont, TX). Diabetes was conﬁrmed 1 week after induc-
tion by measuring the blood glucose level. A minimum of four
animals were examined for each time point. A second group of
animals was induced with T1D and fed either minocycline-
supplemented chow (1 g/kg of food) or control chow (Purina
Mills, Gray Summit, MO) at 14 days after T1D induction and
sacriﬁced at 10weeks. The relative density of ionized calcium-
binding adapter molecule 1 (Iba-1)þ microglia/macrophages
was determined in the HYPO and compared with T1D mice
without minocycline treatment and age-matched control
animals.
Tissue Processing
After conﬁrmed diabetes of durations 4, 8, 12, 35, and 42
weeks, diabetic animals and age-matched controls were
deeply anesthetized and perfused intracardiac with PBS,
followed by 4% paraformaldehyde in 0.1 mol/L PB. Brains
were immersion ﬁxed overnight, followed by cryoprotection
in 20% sucrose/PB and mounted in optimal cutting temper-
ature compound. Serial cross sections of brains (20 mm thick)
were cut on a cryostat and mounted. Retinal whole mounts
were prepared at 35 weeks after diabetes induction26 and
examined using immunohistochemistry (IHC).
Immunoﬂuorescence Histochemistry
Slides and/or whole mounts were reacted with Iba-1 (Wako,
Osaka, Japan) for visualization of microglia/macrophages27;
and with biotinylated Griffonia simplicifolia (Bandeiraea)
isolectin B4 (GS lectin; Sigma-Aldrich, St. Louis, MO) for
endothelial cells and activated microglia/macrophages. The
tissues were washed and transferred to species-speciﬁc
secondary antibodies conjugated with either Alexa594 or
Alexa488 (InvitrogeneMolecular Probes, Carlsbad, CA).
The sections and whole mounts were then examined under
either epiﬂuorescence or spinning-disc confocal microscopy.
Quantitative Analysis of Iba-1þ Microglia/
Macrophages
Iba-1þ microglia/macrophage density at 4, 8, 12, 35, and 42
weeks after diabetes induction was examined in the HYPO,1610granular insular cortex (GIC), and basal nuclear region
(BN) of the brain, as well as Iba-1þ microglia/macrophage
densities in retinal whole mounts from diabetic and control
mice. For each region or tissue, three or more images were
taken from different sections for analysis. The density of
Iba-1þ microglia/macrophages was quantiﬁed using ImageJ
software version 1.43u (NIH, Bethesda, MD). To account
for variation, the density of Iba-1þ microglia was normal-
ized by dividing by the mean values of age-matched
controls in the same region or tissue, and expressed as the
percentage of relative densities for each animal.
Quantitative Analysis of Iba-1þ Alone, Iba-1þ/GFPþ
Microglia/Macrophages, and GFPþ Alone Bone Marrow
Cells
To count all positive cells in different focal planes in the
same areas, the positive cells were counted while under
microscopic observation. For Iba-1þ alone, Iba-1þ/GFPþ,
and GFPþ alone cells, sequential captures on each (for CY3,
CY3/ﬂuorescein isothiocyanate, and ﬂuorescein iso-
thiocyanate) plane were made. The relative density was
determined for each group, and a mean and SE were
determined, where P < 0.05 indicated signiﬁcant differ-
ences using one tailed t-tests.
Quantitative Analysis of c-Fos
The polyclonal rabbit antiec-Fos antibody (sc-52; Santa Cruz
Biotechnology, Santa Cruz, CA) and mouse anti-neuronal
nuclei (NeuN, monoclonal antibody 377; Chemicon, Teme-
cula, CA) were used for these studies. Four mice from each
group (control, diabetic 12 weeks, and diabetic þ minocy-
cline) were used and three to four images were taken from each
mouse (10 magniﬁcation confocal images; 0.9  0.9 mm).
The density of c-fosþ cells was quantiﬁed using ImageJ
software.
Results
Diabetes Reduces Sympathetic Neuronal Connections
to the Bone Marrow
To examine the connections between the bone marrow and
the CNS, PRVeGFP was administered into the bone
marrow cavity of normal nondiabetic mice. Time course
studies of neuronal labeling after bone marrow injection
with PRV-152 showed spinal cord cells labeled within 24 to
48 hours, brainstem nuclei at 3 to 4 days, and hypothalamic
nuclei at 6 days, supporting a polysynaptic-speciﬁc brain-
bone circuit. Intense CNS labeling was seen 7 days after
bone marrow injection. Retrograde transport of the virus
produced labeling in SNS-associated nuclei, including the
PVN (Supplemental Figure 1A), nucleus tractus solitarii
(Supplemental Figure 1B), rostral ventrolateral medulla
(Supplemental Figure 1C), caudal raphe, and noradrenergicajp.amjpathol.org - The American Journal of Pathology
CNS Inﬂammation in T1Dnuclei of the subfornical organ (Supplemental Figure 1D).
Our data show a clear polysynaptic link between brain and
bone marrow. It is known that the virus replicates in the
soma and travels only in a retrograde direction; thus, the
brain regions labeled are efferent systems that maintain
heterosynaptic connections with the bone marrow.
Because of the small size of the bone marrow cavity of
mice, viral-tracing patterns were conﬁrmed in nondiabetic
rats to control for possible leakage during murine injections.
Rats showed robust GFP labeling in the PVN (Figure 1A).
To assess the impact of T1D diabetes on the bone marrow
CNS connections, T1D rats with 2 months’ duration of
disease received an injection of PRV-GFP into the bone
marrow cavity (Figure 1B). Quantitation of GFPþ neurons
in the age-matched control and diabetic groups (Figure 1C)
showed reduced numbers of GFP-labeled neurons in the
PVN (P < 0.05) of the diabetic rat, supporting the loss of
innervation and presence of peripheral neuropathy associ-
ated with the bone marrow.
Diabetic Loss of Neural Control in Bone Marrow Alters
Neurotransmitter Balance and Changes Hematopoiesis
toward Generation of Monocytes
To further characterize the reduced neural projections, we
examined the bone marrow using IHC of neurotransmitters.
In 2-month-old T1D rats, tyrosine hydroxylaseepositive
axons were reduced by 37% (P < 0.05); however, there
were no signiﬁcant differences in calcitonin gene-related
peptide, acetylcholine, somatostatin, and vasoactive intes-
tinal peptide (Figure 2, AeK). We next examined levels of
proinﬂammatory cytokines in the bone marrow supernatant
of mice with 1 and 9 months of diabetes and compared
levels with age-matched control mice. Notably, there were
age-related changes [speciﬁcally, an age-related decrease in
IL-1b, IL-3, and IL-10 and an age-related increase in IL-6
and tumor necrosis factor a (TNF-a)]. In diabetes, the
reduction in neurotransmitters was associated with an
increase in IL-1b and TNF-a (Figure 3A). Age-related
decreases were observed in stromal cell-derived factor-1,
stem cell factor, granulocyte colony-stimulating factor (G-
CSF), and insulin-like growth factor-1 (IGF-1) (Figure 3B)Figure 1 Tracing with GFP-labeled pseudo rabies virus (PRV) shows neural conn
rats. Injection of PRV-152 GFP into the bone marrow (BM) of the femur in rats sho
labeling in the PVN compared with type 1 diabetics rats (B). C: Diabetic rats sho
The American Journal of Pathology - ajp.amjpathol.orgin the bone marrow supernatant. In the diabetic mice, we
observed an increase in vascular endothelial growth factor
and G-CSF and a decrease in IGF-1 at 9 months of T1D
when compared with age-matched controls. An age-related
decrease in both matrix metalloprotease (MMP)-2,
required for mobilization of cells from the bone marrow,
and MMP-9 was observed. Both MMP-2 and MMP-9 were
decreased at 1 month of T1D compared with age-matched
controls (Figure 3C), and MMP-9 was decreased in the
diabetic mice at 9 months compared with age-matched
controls.
To determine whether there is a functional alternation in
brainebone marrow communication, we examined the
circadian release pattern of bone marrow cells into the
circulation of diabetic rodents and human subjects compared
with controls. Twenty-four hour sampling of peripheral
blood of T1D rats (Figure 4A) showed monocytosis
throughout the entire period. This circadian pattern was
associated with a phase shift in the peak of monocytes in
T1D rats compared with age- and sex-matched controls,
suggesting that CNS-controlled neural signals regulating
monocyte mobilization are altered in diabetes. These ﬁnd-
ings in diabetic rats were corroborated in a small cohort of
human T1D subjects (Figure 4B).
Diabetes Results in an Accumulation of Bone
MarroweDerived Inﬂammatory Cells in the
Sympathetic Regions of the CNS
To determine whether the observed systemic monocytosis
had any consequences in the CNS, we assessed the contri-
bution of bone marrowederived cells to CNS inﬂammation
in T1D and control mice by generating bone marroweGFPþ
chimeric mice and examining them for CNS inﬂammation.
Iba-1 was used as a marker for macrophage/microglia acti-
vation, the intensity of which increases in activated micro-
glia.28 Sections were collected from the most rostral
extension of the PVN to the most caudal aspect, and within
each section the areas quantiﬁed for microglia activation
included all subdivisions of the PVN, the lateral hypothal-
amus, the anterior hypothalamic area, and the ventral medial
hypothalamic nucleus (collectively termed HYPO). Theections between the sympathetic nervous system (SNS) and bone marrow in
ws differential tracing with disease state. Control rats (A) show robust GFP
w fewer GFP-labeled neurons in the PVN. *P < 0.05.
1611
Figure 2 Key neurotransmitters in bone marrow are reduced in type 1 diabetic rats. Calcitonin gene-related peptide (CGRP) was reduced by 29% in control
(A) compared with diabetes (B; not signiﬁcant), tyrosine hydroxylase (TH) was reduced by 37% in control (C) compared with diabetes (D; P < 0.05),
acetylcholine (Ach) was slightly increased by 9% in control (E) compared with diabetes (F), somatostatin was reduced by 13% in control (G) compared with
diabetes (H), and vasoactive intestinal peptide (VIP) was reduced by 13% in control (I) compared with diabetes (J). K: Quantitative data.
Hu et aldensities of GFPþ/Iba-1þ bone marrowederived macro-
phage populations and GFP/Iba-1þ activated resident
microglia were determined in the HYPO, GIC, and BN
which served as an adjacent control region (Figure 5, AeI).
The sympathetic-associated HYPO and GIC regions were
found to show marked inﬂammation in contrast to the BN
region (Figure 5G). GFPþ/Iba-1þ cells represent the bone
marrowederived macrophages that have extravasated into
the CNS tissue parenchyma and have produced Iba-1þ
macrophages (Figure 5, AeF). GFPþ/Iba-1þ bone mar-
rowederived macrophages were compared in control
(Figure 5, AeC) and diabetic (Figure 5, DeF) mice. The
proportion of Iba-1þ/GFPþ bone marrowederived macro-
phages, expressed as a percentage of total Iba-1þ macro-
phages, increased signiﬁcantly in the HYPO (22.0% versus
4.0%) and GIC (14.1% versus 2.1%) groups at 8 weeks after
the induction of diabetes compared with control (P < 0.05)
(Figure 5H). No signiﬁcant differences were observed in BN
(3.9% versus 3.0%) between conditions. Thus, in T1D, both
activated resident microglia and bone marrowederived
macrophages contribute to inﬂammation in the sympathetic
regions of the CNS.
A time course study was performed to determine whether
the changes we observed early in T1D were persistent with
longer duration of disease. In the T1D mice, the density of
Iba-1þ microglia was signiﬁcantly increased in the HYPO
and GIC (P < 0.05) at all ﬁve time points examined (4, 8,
12, 35, and 42 weeks after diabetes induction) (Figure 5I)
relative to age-matched controls.1612SNS-Associated Brain Regions Exhibit Increased
Inﬂammatory Cytokine Levels
mRNA levels of cytokines were examined in SNS-associated
regions that showed increased bone marrowederived ma-
crophages in diabetes. In mice with 8 weeks of T1D, a 1.4-
fold increase in interferon-g mRNA was found in both the
HYPO and GIC (P < 0.05) compared with controls. CCL2
and IL-1b mRNAs were similarly increased, with 2.2-fold
(P < 0.05) and 1.6-fold (P < 0.05) increases, respectively,
in the HYPO of diabetics compared with controls. However,
no changes in IL-6, IL-12, and TNF-a were evident.
Pharmacological Inhibition of Neuroinﬂammation
Pathways with Minocycline Reduces Inﬂammatory Cell
Numbers in SNS Regions
We hypothesize that a CCR2þ monocyte subset contributed
to the pool of mononuclear cells in the brain regions
affected by diabetes, including the HYPO. To test this, brain
regions were dissected and then digested for analysis by
FACS.29 Levels of GR-1þ, CCR2þ, and CD45þ cells are
increased in the PVN region of diabetic mice (Figure 6,
AeC), and these levels could be decreased by treatment of
diabetic mice with minocycline, an anti-inﬂammatory agent
that crosses the BBB (Figure 6, DeF).
The brains of diabetic mice treated with minocycline were
also examined for the frequency of Iba-1þ macrophages/
activatedmicroglia, as assessed by staining andmorphologicalajp.amjpathol.org - The American Journal of Pathology
Figure 3 Cytokines/growth factors measured in bone marrow super-
natant by ELISA. Diabetes results in alteration in the levels of cytokines and
growth factors in bone marrow supernatant. The bone marrow supernatant
of 1- and 9-month diabetic and age-matched control mice was analyzed. A:
Age-related changes were observed (speciﬁcally, an age-related decrease in
IL-1b, IL-3, and IL-10 and an age-related increase in IL-6 and TNF-a. In
diabetes, the reduction in neurotransmitters was associated with an
increase in IL-1b and TNF-a. B: Age-related decreases were observed in
stromal-derived factor-1 (SDF-1), stem cell factor (SCF), granulocyte colony
stimulating factor (G-CSF), and IGF-1. In the diabetic mice, an increase in
vascular endothelial growth factor (VEGF) and G-CSF and a decrease in IGF-1
at 1 month of T1D were observed. C: An age-related decrease in both MMP-2
and MMP-9 was observed. Both MMP-2 and MMP-9 were decreased at 1
month of T1D compared with age-matched controls, and MMP-9 was
decreased in the diabetic mice at 9 months compared with age-matched
controls. *P < 0.05 for diabetes compared with age-matched control; yP
< 0.05 for 9-month control compared with 1-month control; and zP < 0.05
for 9-month diabetes compared with 1-month diabetes. n.d., not done.
Figure 4 Twenty-four hour monitoring of peripheral blood showed an
increase in the numbers of monocytes in the circulation and a phase shift in
peak levels in diabetes. Twenty-four hour monitoring of peripheral blood of
type 1 diabetic rats (PT; A) and diabetic humans and controls (B) was
performed. In both rats and humans, diabetes was associated with more
monocytes in the circulation and a phase shift in peak levels compared with
age- and sex-matched controls, suggesting that diurnal-controlled neural
signals inﬂuenced monocyte mobilization and were altered in diabetes. The
monocytes were plotted by individual points and a cosine functioneﬁtted
curve for rats (A), and by individual points with a line conjugated for each
human patient and a ﬁtted curve derived from a nonlinear mixed-effects
model with cosine function (B). WBC, white blood cell; ZT, Zeitgeber time.
CNS Inﬂammation in T1Dfeatures. The density of Iba-1þ cells increased signiﬁcantly in
T1D mice (Figure 6, G, H, and J). Minocycline treatment in
T1D resulted in an 18.3% reduction in Iba-1þ cell density in
theHYPO(P< 0.05) (Figure 6, I and J) comparedwith control
mice.
As a known target tissue of diabetic complications, we
next examined the retina of T1D mice for the presence of
Iba-1þ macrophages/activated microglia. T1D mice showedThe American Journal of Pathology - ajp.amjpathol.orgsigniﬁcantly more Iba-1þ and GS IB4þ double-labeled
macrophages/activated microglia (also shown around GS
IB4þ blood vessels) compared with control (Figure 6, K, L,
and N). Quantitative analysis of Iba-1þ microglia showed
that minocycline treatment reduced the numbers of Iba-1þ
cells in diabetic animals to those found in age-matched
control retina (Figure 6, M and N).
The proto-oncogene, c-Fos, is a regulator of cytokine
expression and an important modulator in inﬂammatory
processes.30 In the CNS, there is only a low constitutive
level of c-Fos expression in neuronal cells of adult animals
under normal conditions.31 However, various extracellular
stimuli transiently induce the expression of c-Fos mRNA
and protein in mammalian neurons.31 The expression of c-
Fos in the CNS also is remarkably increased in T1D rats.30
The increased expression of c-Fos in neurons in diabetic
HYPO is thought to contribute to the elevated levels of
vasopressin and autonomic dysfunction during diabetes.30
For these reasons, we examined c-Fos expression IHC in1613
Figure 5 Activated resident microglia and GFPþ bone marrowederived macrophages both contribute to inﬂammation in the hypothalamus (HYPO) and
granular insular cortex (GIC) in type 1 diabetes (T1D). By using chimeric GFP mice, three populations of cells were identiﬁed: Ibaþ resident microglia/
macrophages, GFPþ bone marrowederived cells and Iba-1þ/GFPþ bone marrowederived macrophages. Representative Iba-1þ/GFPþ bone marrowederived
macrophages (arrows) in HYPO of control (AeC) and T1D diabetic (DeF) mice. G: Schematic diagram of a brain section showing the location of the three brain
regions analyzed. H: The percentage of Iba-1þ/GFPþ bone marrowederived macrophages as a percentage of total Iba-1þ microglia/macrophages increased
signiﬁcantly in diabetic brains compared with control in HYPO and GIC, but not in the BN. I: Quantitative analysis of the relative density of Iba-1þ cells showed
a statistically signiﬁcant increase in the density of Iba-1þ cells in diabetic versus control brains in HYPO and GIC from 4 to 42 weeks. However, in the BN, the
density was not increased at all postinduction time points. Scale bar Z 100 mm (in B for images in AeF). *P < 0.05.
Hu et althe HYPO, a region of the CNS that has polysynaptic
connections with bone marrow (Figure 1) and increased
neuroinﬂammation in T1D (Figure 7). The total number of
c-Foseexpressing cells, and c-Fosþ/NeuNþ cells, was
determined in the HYPO of control, T1D, and T1D plus
minocycline-treated mice. In control HYPO mice, there
were some weakly c-Fosþ cells (Figure 7A). To determine
the cell type expressing c-Fos, we undertook double staining
for c-Fos and NeuN antigens. Approximately 89% of the c-
Fosþ cells were double labeled with NeuN, representing
neurons (Figure 7, B and G). c-Fos expression was
increased approximately twofold in the HYPO of T1D mice
(P < 0.003 versus control), especially in the periventricular1614region (Figure 7, C, D, and G). In the HYPO of T1D mice
treated with minocycline, the density of c-Fosþ/NeuNþ cells
was signiﬁcantly reduced when compared with HYPO of
untreated T1D mice (P < 0.05) (Figure 7, EeG).Discussion
In this study, we identify a loss of key neurotransmitters in
the bone marrow that is associated with increased inﬂam-
matory cytokines and decreased growth factor expression.
These critical changes resulted in a shift in hematopoiesis
toward generation of predominantly monocytes.32 The boneajp.amjpathol.org - The American Journal of Pathology
CNS Inﬂammation in T1Dmarrow within the large bones produces new blood cells and
stem/progenitor cells, with both the generation and the release
of these cells into the circulation being dynamically and
precisely regulated by the sympathetic nervous system.10The American Journal of Pathology - ajp.amjpathol.orgPreviously, we demonstrated that there exists a dramatic
reduction in the numbers of sympathetic terminals in the bone
marrow in type 2 diabetes.11 In the present study, we show
this for T1D mice and rats. This denervation with loss of
neurotransmitters and neuropeptides promotes changes in
the bone marrow microenvironment associated with in-
creased inﬂammatory cytokines and decreased growth factor
expression (Figure 3). The denervation also changes the
circadian pattern of release of bone marrow cells into the
circulation and supports changes in neuronal function to the
bone marrow.
In diabetic rodents, changes in the diurnal rhythm of
monocyte release are observed with both an increase in
amplitude of peak release and a phase shift compared with
age-matched controls. This same abnormal pattern is
observed in the T1D human subjects we studied compared
with nondiabetic controls. Blood leukocyte numbers have
long been known to exhibit circadian oscillations.33
However, to our knowledge, we are the ﬁrst to show this
distinct difference in diabetes. The current ﬁndings are in
agreement with our previous published studies showing
a disturbed pattern of release of endothelial progenitor cells
from the bone marrow in T1D.11 Thus, bone marrow
neuropathy shifts hematopoiesis toward fewer vascular
progenitors and increased generation of monocytes, which,
when released into the peripheral blood, home to brain
regions expressing cytokines, such as CCL2. Although we
have demonstrated the speciﬁcity of the inﬂammation in
regions anatomically connected with the bone marrow, it
remains to be determined why these regions respond to
hyperglycemia by increasing CCL2 expression. Increased
microglia activation and localization in the PVN and centers
of the autonomic nervous system are not transient events,Figure 6 Minocycline reduces monocyte/macrophage inﬁltration in the
diabetic hypothalamus and retina. AeF: Single-cell suspensions made from
collagenase-digested tissue were analyzed for CD45þ expression. CD45þ-
gated events were subsequently analyzed for CCR2þ and GR-1þ. Levels of
GR-1þ/CCR2þ cells are increased in the paraventricular nucleus (PVN)
region of diabetic mice (AeC) and are decreased by treatment of diabetic
mice with minocycline (DeF). The IHC analysis in the hypothalamus (HYPO)
detects the presence of Iba-1þ cells in control (G), untreated type 1 dia-
betes (T1D) mice at 12 weeks (H), and T1D mice treated with minocycline
(I). J: Quantitation of Iba-1þ cell density in control, T1D, and T1D with
minocycline showed that the density of Iba-1þ cells increased in diabetes,
and minocycline reduced the number of Iba-1þcells in the HYPO to levels
observed in control mice. The IHC staining with Griffonia simplicifolia iso-
lectin to detect blood vessels in the retina, and Iba-1þ (red) shows the
presence of activated microglia in proximity to retinal blood vessels of
control, T1D, and T1D with minocycline mice (KeM). K: Retina of age-
matched control mice shows low levels of GS lectin expression on Iba-1þ
resting ramiﬁed microglia. L: There is marked up-regulation of GS lectin and
Iba-1 expression and change in microglial morphological characteristics
and increased density in T1D. M: Treatment of T1D mice with minocycline
reduced the density of Iba-1þeactivated microglia, similar to that
observed in control retina. N: Cumulative quantitation of cell density
conﬁrms increased Iba-1þ cell density in the retinal vasculature of diabetic
mice, which is reduced to the control level with minocycline treatment. *P
< 0.05. Scale bar Z 50 mm (in G and K for images in GeI and KeM).
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Figure 7 c-Fosþ expression is increased in type 1 diabetes (T1D), and this increase is partially mitigated by minocycline. The IHC analysis of c-Fos and NeuN
labeling in the hypothalamus (HYPO) of control (A and B), untreated type 1 diabetic mice at 12 weeks (C and D), and diabetic mice treated with minocycline (E
and F). Two populations of cells were counted in each experimental group: total c-Fosþ cells (arrowheads) and c-Fosþ/NeuNþ cells (arrows). c-Fosþ cell density
increased in diabetic HYPO, especially in the periventricular region (C and D) whereas minocycline treatment in T1D dampened c-Fos expression in T1D (E and F).
G: Minocycline treatment reduced c-Fosþ cell density. Quantitation of c-Fosþ cell density in the three groups conﬁrms that both total c-Fos cells and c-Fosþ/
NeuNþ neurons are increased in diabetes when compared with control age-matched mice (*P< 0.003), and minocycline reduced the number of c-Fosþcells in the
HYPO signiﬁcantly lower than that in T1D (*P < 0.05), but the number was still higher than that found in controls (yP < 0.05). Scale barZ 100 mm (in A for
images in AeF). V, position of the third ventricle.
Hu et albut they occur at early (4 to 8 weeks), mid (12 weeks), and
late (35 to 42 weeks) stages of diabetes.
In addition to the well-accepted peripheral neuropathy
associated with diabetes, there is the involvement of the
autonomic nervous system in diabetes, and this condition
affects multiple tissues and organ systems.34e36 SNS brain
regions have connections with all peripheral organs, and this
has been well delineated with the kidney37 and the spleen.38
However, the brainebone marrow connection has not yet
garnered much attention and its involvement in diabetic
complications is even less well studied. By using PRV
tracing, the presence of polysynaptic bone marroweSNS
connections was demonstrated; however, the number of
neurons connecting the bone marrow within the SNS centers
is markedly reduced in diabetes, further suggesting the
presence of a peripheral neuropathy affecting bone marrow.
The activated microglial response observed in the bone
marrowerelevant regions of the SNS may be responsible for
the increase in cytokines we observed. Activated microglia
are responsible for the production of reactive oxygen
species and inducible nitric oxide synthase, which diffuse
into adjacent tissues to modulate neural activity and ion
channels and reduce BBB integrity.39 Once in the brain,
bone marrowederived cells can have a powerful effect on
the resident microglia, as described by Chen et al,40 who
showed that defective microglia cause pathological groom-
ing in Hoxb8-mutant mice, and a bone marrow transplant
from wild-type mice modiﬁed the brain microglia and
normalized the pathological grooming of the Hoxb8 mice.
Furthermore, Longo et al41 demonstrated that many1616activated microglia observed in the hippocampus of status
epilepticus mice are derived from bone marrow. Thus, there
seems to be a two-way communication in which the brain
has control of bone marrow hematopoiesis, which can be
severely affected by conditions altering the neural pathways
involved, and bone marrowederived microglia can directly
affect brain activity to modify peripheral control pathways
and behavior.
In our studies, we identiﬁed a marked increase in CCR2þ
monocytes. The major ligand for CCR2 is CCL2, a chemo-
attractant that increases monocyte release from the bone
marrow, attracts monocytes/macrophages into inﬂamed tissue,
and facilitates their transmigration across the microvascular
endothelial cell layers into the brain.20e22 The expression of
CCL2 is virtually undetectable in healthy tissue, but is greatly
increased in diabetics,23 including in the vitreous of patients
with proliferative diabetic retinopathy.42e45 Circulating CCL2
levels are also increased in patients with diabetes.46 Distinct
CCL2 genotypes are associated with diabetic microvascular
complications.47e49 High glucose treatment of endothelial
cells isolated from diabetic subjects resulted in a 40% to 70%
increase of CCL2 release, a 10% to 20% increase of the basal
expression of vascular cell adhesion molecule-1, and an
enhancement of the monocyte-endothelial cell interaction.50
Similarly, 7 days of incubation of human umbilical vein
endothelial cells with high glucose increased mRNA expres-
sion and the production rate of CCL2 in a time-dependent and
concentration-dependent (10 to 35 mmol/L) manner, through
up-regulation of reactive oxygen species and subsequent
activation of p38 mitogen-activated protein kinase.51 Thus,ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Schematic of brainebone marrow communication. Based on
our studies and the published literature, we postulate that a two-way
communication occurs between the brain and the bone marrow. The
sympathetic centers of the brain regulate the release of bone marrow cells
into the circulation, and the innervation of stromal cells also regulates
hematopoiesis. In T1D, the neural pathways involved are adversely
affected, resulting in altered circadian release patterns and the generation
of excessive numbers of monocytes. The bone marrowederived monocytes
that express CCR2 can inﬁltrate the brain, responding to gradients of
cysteine CCL2 generated by hyperglycemia-stimulated neurons. The CCR2þ
monocytes become activated cells and directly affect brain activity to
modify peripheral control pathways. This increase in generation of mono-
cytes results in neuroinﬂammation targeted to the same brain regions that
also inﬂuence the release of bone marrowederived cells in health, with the
sympathetic nervous system (SNS) centers generating a feed-forward
pattern to the neuroinﬂammation.
CNS Inﬂammation in T1Dhyperglycemia promotes increased expression of CCL2. This
was validated in vivo in our study because we observed an
increase in CCL2 mRNA only in regions of the CNS with
direct neuronal connections to the bone marrow.
Our data show that T1D produces elevated c-Fos labeling
in the hypothalamus. Although our current study does not
identify the precise neuronal mechanisms responsible for
elevated cFos, this will be evaluated in future studies. A
causal relationship or exact temporal relationship between
bone marroweconnected neurons, cFos labeling, and cyto-
kine expression can only be implied. All these end points
were measured in brains from different animals because
PRV-152 produces inﬂammation in the regions it labels and
would, thus, confound the c-Fos labeling and the cytokine
measurements. Nevertheless, our data convincingly show
elevated cFos as a result of T1D, brainetoebone marrow
connections, and elevated cytokine expression in T1D. c-Fos
expression in the hypothalamus is colocalized with NeuN,
indicating that most c-Foseexpressing cells are neurons. In
diabetes, neurons in the HYPO can undergo degeneration52
and apoptosis.53 Ultrastructural studies demonstrate that
neurons in the HYPO in STZ-induced diabetic rats exhibit
distension of rough endoplasmic reticulum, swollen mito-
chondria, and enhanced electron density of their cyto-
plasm54,55 and increased arginine, vasopressin, oxytocin,
N-methyl-D-aspartate receptor 1, neuronal nitric oxide syn-
thase, and vasopressin expression, but reduced GluR2/3
expression.56 The hypothalamic neuronal changes in diabetes
have been suggested to be due to hyperglycemia and
hyperosmolality, which triggers an increase in neuronal
activity.53 Thus, the increased c-Fos expression that we
observed in the neurons in the HYPO may be due to both
hyperglycemia and hyperosmolality. c-Fos was found in
increased levels in the same brain regions of diabetics that
demonstrate connections to the bone marrow.
Our results suggest that neuropathy involving the bone
marrow fosters generation of CCR2þ monocytes, whereas
the hyperglycemic environment promotes CCL2 expression
in the SNS centers. This leads to recruitment of bone mar-
rowederived cells that respond to these CCL2 gradients,
facilitating their extravasation and promoting activation of
resident microglia in these regions (Figure 8).
Minocycline treatment resulted in fewer monocytes
inﬁltrating into the HYPO and also fewer activated micro-
glia. Minocycline is a second-generation tetracycline that
effectively crosses the BBB.57 It has remarkable neuro-
protective qualities in models of cerebral ischemia, trau-
matic brain injury, and Huntington’s and Parkinson’s
diseases.58 Minocycline-mediated neuroprotection is asso-
ciated with inhibition of caspase-1, caspase-3, and inducible
nitric oxide synthase transcriptional up-regulation and acti-
vation.59 Inhibitions of p38 mitogen-activated protein
kinase and microglial activation have also been associated
with minocycline-mediated neuroprotection.59
Minocycline prevented the development of diabetic reti-
nopathy in rodent models.60 Animal studies of the efﬁcacy ofThe American Journal of Pathology - ajp.amjpathol.orgminocycline in treating DR in mice show that long-term
administration of the drug successfully prevented retinal
capillary degeneration in diabetic mice.29 In contrast, doxycy-
cline, which is equally effective at reducing inﬂammation but
does not cross the BBB, did not prevent retinopathy in diabetic
rodents.29 Thus, this notion of separating peripheral versus
central effects of minocycline has been examined by the
comparison of doxycycline (peripheral inhibition) to minocy-
cline (both peripheral and central inhibition), and the results
suggest that minocycline was more effective in treatment of
diabetic retinopathy. We and others have used minocycline to
treat diabetic retinopathy in human subjects. In a cohort of
morbidly obese type 2 diabetic subjects, we showed that
minocycline treatment improved visual acuity and symptoms
associated with painful neuropathy. Minocycline-treated
subjects experienced weight loss, reductions in hemoglobin
A1C, and improved blood pressures.
611617
Hu et alMinocycline has also been successfully used to treat painful
diabetic neuropathy,62 and we conﬁrmed this ﬁnding in our
study of subjects with morbidly obese type 2 diabetes.61
Cukras et al63 showed that minocycline treatment of diabetic
subjects with diabetic retinopathy and diabetic macular edema
(DME) resulted in improved visual function, reduced central
DME, and less vascular leakage. They concluded that inhibi-
tion of microglia with oral minocycline may be a promising
therapeutic strategy targeting the inﬂammatory etiology of
DME.63 Our current studies have limitations, however,
because we do not distinguish between the central and
peripheral effects of minocycline, and additional studies need
to be performed before therapeutic targeting of central
inﬂammation is conclusive for management of diabetic reti-
nopathy and other diabetic complications.
In summary, our ﬁndings lead us to suggest that there is
a two-way brainebone marrow communication. The
sympathetic centers of the brain regulate the release of bone
marrow cells into the circulation. The innervation of stromal
cells within the bone marrow regulates hematopoiesis. In
T1D, the neural pathways involved are adversely affected,
resulting in altered diurnal release patterns of monocytes
and in generation of excessive numbers of monocytes. The
bone marrowederived monocytes that express CCR2 inﬁl-
trate the brain, responding to gradients of CCL2 likely
generated by hyperglycemia-stimulated neurons. These
CCR2þ monocytes become activated cells promoting neu-
roinﬂammation in the same sympathetic nervous system
regions that regulate release of bone marrowederived cells.
Acknowledgments
We thank Jane Nappi and Marda Jorgenson for their tech-
nical assistance and Dr. Wolfgang Striet (all from University
of Florida).
P.H., J.S.T., Y.Y., S.H., S.C., T.S., W.L., J.D., A.D.,
A.Z., M.T., S.P.M., and D.R.S. conducted research and
contributed to writing; and M.E.B., J.V.B., M.K.R., T.C.-L.,
and M.B.G. directed research and contributed to writing.
T.C.-L. and M.B.G. are the guarantors of this work, had full
access to all the data, and take full responsibility for the
integrity of data and the accuracy of data analysis.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.07.009.
References
1. Reijmer YD, van den Berg E, Ruis C, Kappelle LJ, Biessels GJ:
Cognitive dysfunction in patients with type 2 diabetes. Diabetes
Metab Res Rev 2010, 26:507e519
2. Yates KF, Sweat V, Yau PL, Turchiano MM, Convit A: Impact of
metabolic syndrome on cognition and brain: a selected review of the
literature. Arterioscler Thromb Vasc Biol 2012, 32:2060e206716183. Miyan JA, Broome CS, Whetton AD: Neural regulation of bone
marrow. Blood 1998, 92:2971e2973
4. Massberg S, Schaerli P, Knezevic-Maramica I, Kollnberger M,
Tubo N, Moseman EA, Huff IV, Junt T, Wagers AJ, Mazo IB, von
Andrian UH: Immunosurveillance by hematopoietic progenitor cells
trafﬁcking through blood, lymph, and peripheral tissues. Cell 2007,
131:994e1008
5. Abboud FM, Harwani SC, Chapleau MW: Autonomic neural regu-
lation of the immune system: implications for hypertension and
cardiovascular disease. Hypertension 2012, 59:755e762
6. Mignini F, Streccioni V, Amenta F: Autonomic innervation of
immune organs and neuroimmune modulation. Auton Autacoid
Pharmacol 2003, 23:1e25
7. Ganta CK, Lu N, Helwig BG, Blecha F, Ganta RR, Zheng L,
Ross CR, Musch TI, Fels RJ, Kenney MJ: Central angiotensin II-
enhanced splenic cytokine gene expression is mediated by the
sympathetic nervous system. Am J Physiol Heart Circ Physiol 2005,
289:H1683eH1691
8. Yi CX, Tschöp MH, Woods SC, Hofmann SM: High-fat-diet expo-
sure induces IgG accumulation in hypothalamic microglia. Dis Model
Mech 2012, 5:686e690
9. Rosas-BallinaM,Olofsson PS, OchaniM, Valdes-Ferrer SI, LevineYA,
Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S,
Mak TW, Tracey KJ: Acetylcholine-synthesizing T cells relay neural
signals in a vagus nerve circuit. Science 2011, 334:98e101
10. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS: Haematopoietic
stem cell release is regulated by circadian oscillations. Nature 2008,
452:442e447
11. Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N,
Caballero S, Player D, Nakagawa T, Afzal A, Kielczewski J,
Sochacki A, Hasty S, Li Calzi S, Kim S, Duclas SK, Segal MS,
Guberski DL, Esselman WJ, Boulton ME, Grant MB: Diabetic reti-
nopathy is associated with bone marrow neuropathy and a depressed
peripheral clock. J Exp Med 2009, 206:2897e2906
12. Yamazaki K, Allen TD: Ultrastructural morphometric study of
efferent nerve terminals on murine bone marrow stromal cells, and the
recognition of a novel anatomical unit: the “neuro-reticular complex.”
Am J Anat 1990, 187:261e276
13. Linton PJ, Dorshkind K: Age-related changes in lymphocyte devel-
opment and function. Nat Immunol 2004, 5:133e139
14. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H,
Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS,
Adamis AP: A central role for inﬂammation in the pathogenesis of
diabetic retinopathy. FASEB J 2004, 18:1450e1452
15. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based
anti-inﬂammatory drugs inhibit the early lesion of diabetic retinop-
athy. Diabetes 2007, 56:337e345
16. Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD,
Madden KS, Olschowki JA, Livnat S: Noradrenergic sympathetic
neural interactions with the immune system: structure and function.
Immunol Rev 1987, 100:225e260
17. Geissmann F, Revy P, Brousse N, Lepelletier Y, Folli C, Durandy A,
Chambon P, Dy M: Retinoids regulate survival and antigen presen-
tation by immature dendritic cells. J Exp Med 2003, 198:623e634
18. Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JL: CCL2/MCP-1
modulation of microglial activation and proliferation. J Neuro-
inﬂammation 2011, 8:77
19. Schilling M, Strecker JK, Ringelstein EB, Schabitz WR, Kiefer R:
The role of CC chemokine receptor 2 on microglia activation and
blood-borne cell recruitment after transient focal cerebral ischemia in
mice. Brain Res 2009, 1289:79e84
20. Huang D, Wujek J, Kidd G, He TT, Cardona A, Sasse ME, Stein EJ,
Kish J, Tani M, Charo IF, Proudfoot AE, Rollins BJ, Handel T,
Ransohoff RM: Chronic expression of monocyte chemoattractant
protein-1 in the central nervous system causes delayed encephalop-
athy and impaired microglial function in mice. FASEB J 2005, 19:
761e772ajp.amjpathol.org - The American Journal of Pathology
CNS Inﬂammation in T1D21. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-
Kossmann MC: Role of CCL2 (MCP-1) in traumatic brain injury
(TBI): evidence from severe TBI patients and CCL2-/- mice. J Cereb
Blood Flow Metab 2010, 30:769e782
22. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP,
Mack M, Charo IF: Critical roles for CCR2 and MCP-3 in monocyte
mobilization from bone marrow and recruitment to inﬂammatory
sites. J Clin Invest 2007, 117:902e909
23. Brucklacher RM, Patel KM, VanGuilder HD, Bixler GV, Barber AJ,
Antonetti DA, Lin CM, LaNoue KF, Gardner TW, Bronson SK,
Freeman WM: Whole genome assessment of the retinal response to
diabetes reveals a progressive neurovascular inﬂammatory response.
BMC Med Genomics 2008, 1:26
24. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS,
Chen DF: Vascular damage in a mouse model of diabetic retinopathy:
relation to neuronal and glial changes. Invest Ophthalmol Vis Sci
2005, 46:4281e4287
25. Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S,
Guberski DL, Kern TS, Grant MB: Ischemic vascular damage can be
repaired by healthy, but not diabetic, endothelial progenitor cells.
Diabetes 2007, 56:960e967
26. Chan-Ling T: Glial, vascular, and neuronal cytogenesis in whole-
mounted cat retina. Microsc Res Tech 1997, 36:1e16
27. Nakano K, Migita M, Mochizuki H, Shimada T: Differentiation of
transplanted bone marrow cells in the adult mouse brain. Trans-
plantation 2001, 71:1735e1740
28. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S:
Microglia-speciﬁc localisation of a novel calcium binding protein,
Iba1. Brain Res Mol Brain Res 1998, 57:1e9
29. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta
signaling prevents degeneration of retinal capillaries in diabetes and
galactosemia. Diabetes 2007, 56:224e230
30. Zheng H, Li YF, Weiss M, Mayhan WG, Patel KP: Neuronal
expression of fos protein in the forebrain of diabetic rats. Brain
research 2002, 956:268e275
31. Morgan JI, Cohen DR, Hempstead JL, Curran T: Mapping patterns of
c-fos expression in the central nervous system after seizure. Science
1987, 237:192e197
32. Hazra S, Jarajapu YP, Stepps V, Caballero S, Thinschmidt JS,
Sautina L, Bengtsson N, Licalzi S, Dominguez J, Kern TS,
Segal MS, Ash JD, Saban DR, Bartelmez SH, Grant MB: Long-
term type 1 diabetes inﬂuences haematopoietic stem cells by
reducing vascular repair potential and increasing inﬂammatory
monocyte generation in a murine model. Diabetologia 2013, 56:
644e653
33. Haus E, Smolensky MH: Biologic rhythms in the immune system.
Chronobiol Int 1999, 16:581e622
34. Kamenov ZA, Traykov LD: Diabetic autonomic neuropathy. Adv
Exp Med Biol 2012, 771:176e193
35. Harrison SA, Brunt EM, Goodman ZD, Di Bisceglie AM: Diabetic
hepatosclerosis: diabetic microangiopathy of the liver. Arch Pathol
Lab Med 2006, 130:27e32
36. Kazakos KA, Saraﬁdis PA, Yovos JG: The impact of diabetic auto-
nomic neuropathy on the incretin effect. Med Sci Monit 2008, 14:
CR213eCR220
37. Cano G, Card JP, Sved AF: Dual viral transneuronal tracing of central
autonomic circuits involved in the innervation of the two kidneys in
rat. J Comp Neurol 2004, 471:462e481
38. Cano G, Sved AF, Rinaman L, Rabin BS, Card JP: Characterization
of the central nervous system innervation of the rat spleen using viral
transneuronal tracing. J Comp Neurol 2001, 439:1e18
39. Peterson JR, Sharma RV, Davisson RL: Reactive oxygen species in
the neuropathogenesis of hypertension. Curr Hypertens Rep 2006, 8:
232e241
40. Chen SK, Tvrdik P, Peden E, Cho S, Wu S, Spangrude G,
Capecchi MR: Hematopoietic origin of pathological grooming in
Hoxb8 mutant mice. Cell 2010, 141:775e785The American Journal of Pathology - ajp.amjpathol.org41. Longo B, Romariz S, Blanco MM, Vasconcelos JF, Bahia L,
Soares MB, Mello LE, Ribeiro-dos-Santos R: Distribution and
proliferation of bone marrow cells in the brain after pilocarpine-
induced status epilepticus in mice. Epilepsia 2010, 51:1628e1632
42. Amann B, Tinzmann R, Angelkort B: ACE inhibitors improve dia-
betic nephropathy through suppression of renal MCP-1. Diabetes
Care 2003, 26:2421e2425
43. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M,
Iwasaki T, Ohno A, Goto H: Increases of vitreous monocyte chemo-
tactic protein 1 and interleukin 8 levels in patients with concurrent
hypertension and diabetic retinopathy. Retina 2011, 31:1951e1957
44. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J: Monocyte chemotactic
protein-1 is a potential player in the negative cross-talk between
adipose tissue and skeletal muscle. Endocrinology 2006, 147:
2458e2467
45. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G,
Csaky KG, Ferris FL 3rd, Chew EY: Serum inﬂammatory markers in
diabetic retinopathy. Invest Ophthalmol Vis Sci 2005, 46:4295e4301
46. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F,
Garancini MP, Ruotolo G, Luzi L, Perseghin G: Association between
plasma monocyte chemoattractant protein-1 concentration and
cardiovascular disease mortality in middle-aged diabetic and nondi-
abetic individuals. Diabetes Care 2009, 32:2105e2110
47. Simeoni E, Hoffmann MM, Winkelmann BR, Ruiz J, Fleury S,
Boehm BO, Marz W, Vassalli G: Association between the A-2518G
polymorphism in the monocyte chemoattractant protein-1 gene and
insulin resistance and type 2 diabetes mellitus. Diabetologia 2004, 47:
1574e1580
48. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Imamura K,
Ishibashi F, Kanda T, Kawai K, Osonoi T, Kashiwagi A,
Kawamori R, Shimomura I, Yamasaki Y: Monocyte chemoattractant
protein-1 (MCP-1) gene polymorphism as a potential risk factor for
diabetic retinopathy in Japanese patients with type 2 diabetes. Dia-
betes Res Clin Pract 2010, 89:e9ee12
49. Moon JY, Jeong L, Lee S, Jeong K, Lee T, Ihm CG, Suh J, Kim J,
Jung YY, Chung JH: Association of polymorphisms in monocyte
chemoattractant protein-1 promoter with diabetic kidney failure in
Korean patients with type 2 diabetes mellitus. J Korean Med Sci
2007, 22:810e814
50. Shanmugam N, Reddy MA, Guha M, Natarajan R: High glucose-
induced expression of proinﬂammatory cytokine and chemokine
genes in monocytic cells. Diabetes 2003, 52:1256e1264
51. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M:
High glucose accelerates MCP-1 production via p38 MAPK in
vascular endothelial cells. Biochem Biophys Res Commun 2003,
305:122e128
52. Luo Y, Kaur C, Ling EA: Neuronal and glial response in the rat
hypothalamus-neurohypophysis complex with streptozotocin-induced
diabetes. Brain Res 2002, 925:42e54
53. Klein JP, Hains BC, Craner MJ, Black JA, Waxman SG: Apoptosis of
vasopressinergic hypothalamic neurons in chronic diabetes mellitus.
Neurobiol Dis 2004, 15:221e228
54. Dheen ST, Tay SS, Wong WC: Ultrastructural changes in the
hypothalamic supraoptic nucleus of the streptozotocin-induced dia-
betic rat. J Anatomy 1994, 184(Pt 3):615e623
55. Dheen ST, Tay SS, Wong WC: Ultrastructural changes in the
hypothalamic paraventricular nucleus of the streptozotocin-induced
diabetic rat. Acta Anat 1994, 149:291e299
56. Fernstrom JD, Fernstrom MH, Kwok RP: In vivo somatostatin,
vasopressin, and oxytocin synthesis in diabetic rat hypothalamus. Am
J Physiol 1990, 258:E661eE666
57. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN,
Patel IR, Abramson SB: A novel mechanism of action of tetracy-
clines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A
1996, 93:14014e14019
58. Sanchez Mejia RO: Friedlander RM: Caspases in Huntington’s
disease. Neuroscientist 2001, 7:480e4891619
Hu et al59. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S,
Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S,
Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c
release and delays progression of amyotrophic lateral sclerosis in
mice. Nature 2002, 417:74e78
60. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L: Relation
between lipophilicity and pharmacological behavior of minocycline,
doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob
Agents Chemother 1975, 8:713e720162061. Yellowlees Douglas J, Bhatwadekar AD, Li Calzi S, Shaw LC,
Carnegie D, Caballero S, Li Q, Stitt AW, Raizada MK: Grant MB:
Bone marrow-CNS connections: implications in the pathogenesis of
diabetic retinopathy. Prog Retin Eye Res 2012, 31:481e494
62. Dray A: Neuropathic pain: emerging treatments. Br J Anaesth 2008,
101:48e58
63. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT: Oral minocy-
cline for the treatment of diabeticmacular edema (DME): results of a phase
I/II clinical study. Invest Ophthalmol Vis Sci 2012, 53:3865e3874ajp.amjpathol.org - The American Journal of Pathology
